NASDAQ: CLRB - Cellectar Biosciences, Inc.

半年間の収益性: -87.03%
セクタ: Healthcare

プロモーションスケジュール Cellectar Biosciences, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

さらに詳しく
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA -0.0142
EV/EBITDA -0.532
IPO date 2005-11-10
ISIN US15117F8077
Industry Biotechnology
P/BV 1.95
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cellectar.com
Цена ао 3.85
Число акций ао 0.01222 млрд
1日あたりの価格変動: +0.6519% (0.3068)
週ごとの価格変動: +31.4% (0.235)
月ごとの料金変更: -79.82% (1.53)
3ヶ月間の価格変動: -84.86% (2.04)
半年間の価格変動: -87.03% (2.38)
年間の価格変動: -88.85% (2.77)
3年間の価格推移: -52.54% (0.6507)
5年間の価格推移: -81.17% (1.64)
10年間の価格推移: 0% (0.3088)
年初からの価格変動: -88.85% (2.77)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV -23.25 0
P/E 0 0
EV/EBITDA -0.5809 0
合計: 2.5

効率

名前 意味 学年
ROA, % -314.55 0
ROE, % 2801.05 10
合計: 3.33

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0.5857

義務

名前 意味 学年
Debt/EBITDA -0.0143 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -187.41 0
収益性 Ebitda, % 173.02 10
収益性 EPS, % -82.81 0
合計: 6
さらに詳しく

機関 音量 共有, %
Nantahala Capital Management, LLC 2701156 8.37
Rosalind Advisors, Inc. 2005658 6.22
AIGH Capital Management LLC 1915220 5.94
Adar1 Capital Management, LLC 1378082 4.27
Worth Venture Partners, LLC 693909 2.15
Vanguard Group Inc 482890 1.5
Acuta Capital Partners LLC 477500 1.48
Citadel Advisors Llc 69007 0.21
Geode Capital Management, LLC 68870 0.21
Blackrock Inc. 57042 0.18

ETF 共有, % 年間の利益率, % 配当金, %
iShares Micro-Cap ETF 0.01881 11.903735012508 1.54048



スーパーバイザー 役職 支払い 生年
Mr. James V. Caruso President, CEO & Director 1.14M 1959 (65 年)
Mr. Chad J. Kolean CPA VP, CFO & Secretary 711.23k 1964 (60 年)
Mr. Jarrod Longcor Chief Operating Officer 854.24k 1973 (51 年)
Mr. Darrell Shane Lea Chief Commercial Officer N/A 1974 (50 年)
Dr. Andrei Shustov M.D. Senior Vice President of Medical N/A 1972 (52 年)

住所: United States, Florham Park. NJ, 100 Campus Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.cellectar.com